Morphic/MORF

$28.75

0.87%
-
1D1W1MYTD1YMAX

About Morphic

Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.

Ticker

MORF

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Bruce Rogers

Employees

121

Headquarters

Waltham, United States

Morphic Metrics

BasicAdvanced
$1.43B
Market cap
-
P/E ratio
-$3.49
EPS
1.47
Beta
-
Dividend rate
$1.43B
1.46624
$63.08
$19.35
493.41K
28.936
-27.88%
-29.08%
-28.99%
2,737.161
2.034
2.046
-99.26%
-120.46%
-77.37%

What the Analysts think about Morphic

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 8 analysts.
97.39% upside
High $76.00
Low $30.00
$28.75
Current price
$56.75
Average price target

Morphic Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-40.7M
12.43%
Profit margin
0%
-

Morphic Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 13.06%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.90
-$0.92
-$0.73
-$0.96
-
Expected
-$0.81
-$0.87
-$0.95
-$0.85
-$0.93
Surprise
10.77%
5.48%
-23.52%
13.06%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Morphic stock?

Morphic (MORF) has a market cap of $1.43B as of April 24, 2024.

What is the P/E ratio for Morphic stock?

The price to earnings (P/E) ratio for Morphic (MORF) stock is 0 as of April 24, 2024.

Does Morphic stock pay dividends?

No, Morphic (MORF) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next Morphic dividend payment date?

Morphic (MORF) stock does not pay dividends to its shareholders.

What is the beta indicator for Morphic?

Morphic (MORF) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Morphic stock price target?

The target price for Morphic (MORF) stock is $56.75, which is 97.39% above the current price of $28.75. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Morphic stock

Buy or sell Morphic stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing